INSIGHT 2 is an ongoing phase II trial of tepotinib plus osimertinib in advanced EGFR-mutant NSCLC with acquired resistance to first-line osimertinib and with MET amplification determined by FISH with GCN of 5 or greater or MET/CEP7 of 2 or greater [54]. The gene discussed is MET; the disease is non-small cell lung carcinoma.